Answers are grounded in this paper and cite their sources.
A single-center retrospective study demonstrates survival benefits of BTK inhibitors in Waldenström macroglobulinemia, suggesting an important treatment option.
Although rare, histologic transformation from WM to DLBCL exhibits aggressive clinical behavior, frequent extranodal involvement, and poor prognosis. BTKi-based regimens may provide significant survival benefits in this patient population.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: